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Incidences of oral tongue, base of the tongue, and tonsil cancers have been increasing steadily in many parts of the world in spite of
declining rates of tobacco use over the last four decades. A better understanding of the etiology, interactions between risk factors,
and new approaches to prevention and treatment are necessary to change this course. This paper will present evidence supporting
a potential role of chronic inﬂammation in the etiologies of oral human papillomavirus infection and head and neck squamous
cell carcinoma, and it will discuss the implications for prevention and treatment.
1.Introduction
Over 500000 new cases of head and neck squamous cell
carcinoma (HNSCC) occur annually in the world [1]. The
National Cancer Institute’s Surveillance, Epidemiology, and
End Results (SEER) has reported a steady increase in the
incidence of oropharyngeal cancers since 1973 despite the
signiﬁcant decline in tobacco use since 1965 [2]. Similar
trends are observed in many parts of the world [3–5].
HNSCC is largely preventable, yet the majority of
current research has focused on treatment and diagnosis.
Most of the existing prevention strategies for HNSCC have
been secondary and tertiary with limited success [6, 7].
Chemoprevention, including retinoids, selenium, vitamin
E, interferon-α (IFN-α), cyclo-oxygenase-2 (COX-2), and
epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors, usually have obstacles including toxicity and
reversal of their eﬀects after cessation of treatment [8, 9].
Primary prevention strategies, focused mainly on smoking
cessation, have not lead to a visible reduction in HNSCC
incidence [1, 2]. Oral human papillomavirus (HPV) infec-
tion has emerged as an independent etiological factor for
at least a subset of HNSCC, and is another target for
primary prevention [10–12]. A highly eﬀective vaccine is
availabletopreventcervicalHPVinfectionwhichiscurrently
recommended for females aged 9 to 26 years and males
a g e d9t o2 1y e a r s[ 13]. However, oral HPV infection can
be transmitted at or any time after birth, and the target
population for the vaccine to prevent oral HPV infection
has not been deﬁned [14]. A large percentage of the general
population who are already exposed to the virus or those
whoalreadydevelopedanHPV-relateddiseasedonotbeneﬁt
from the current vaccine. A better understanding of the
etiology of HNSCC, especially the interactions among risk
factors, is critical for eﬀective prevention strategies.
This short review will (1) present evidence supporting
a potential role of chronic inﬂammation on the etiologies
of oral HPV infection and HNSCC and (2) discuss the
implications for prevention and treatment.
2. Chronic Inﬂammation and Head and Neck
SquamousCellCarcinoma
Clinical, epidemiologic, and animal studies support an
association between chronic inﬂammation and cancer in
several organs [15–18]. Chronic cervicitis and cervical
cancer, ulcerative colitis and colorectal cancer, pancreatitis
and pancreatic cancer, skin inﬂammation and skin cancer,
esophagitis and esophageal cancer, and hepatitis and liver
cancer are a few examples (Table 1).
Intheoralcavity,periodontitisisachronicinﬂammatory
disease of the structures around teeth associated with dental2 International Journal of Otolaryngology
Table 1: Chronic inﬂammatory diseases and associated cancers.
Chronic inﬂammation Associated neoplasm
Chronic bronchitis Lung carcinoma
Chronic gastritis Gastric adenocarcinoma
Chronic cervicitis, pelvic inﬂammatory disease Cervical carcinoma, ovarian carcinoma
Asbestosis, silicosis Mesothelioma, lung carcinoma
Chronic ulcerative colitis Colorectal cancer
Chronic pancreatitis, hereditary pancreatitis Pancreatic carcinoma
Chronic sunburned skin, skin inﬂammation Melanoma, basal-cell carcinoma, squamous cell carcinoma
Reﬂux esophagitis, Barrett’s esophagus Esophageal carcinoma
Chronic hepatitis Hepatocellular carcinoma
Mononucleosis Burkitt’s, Hodgkin’s and non-Hodgkin’s lymphoma.
Chronic cystitis Bladder cancer
Chronic osteomyelitis Skin carcinoma in draining sinuses
Table compiled from [15–18].
bioﬁlm [19]. The ensuing chronic inﬂammation leads to
local pathologic anatomic changes, namely, periodontal
pocket formation, clinical attachment loss (CAL), and
alveolar bone loss (ABL) [20]. As the disease progresses and
more bone is lost, junctional epithelium at the bottom of the
periodontal pocket migrates apically along the root surface
and the pocket depth increases. Untreated periodontitis
eventually leads to tooth loss. The pocket epithelium is
characterized by continuous proliferation, formation of
rete-ridges, and ulcerations. In the connective tissue, there
is increased angiogenesis, chronic inﬂammatory inﬁltrate,
ﬁbrosis, and connective tissue loss. The average prevalence
of periodontitis in the general population is 30% [21].
Periodontitis results in a continuous release of inﬂammatory
cytokines, enzymes, and toxins into saliva. The levels of these
inﬂammatory markers in saliva is directly associated with
the extent and severity of periodontitis [22, 23]. In addition,
periodontal pathogens and inﬂammatory cytokines can
travel with saliva and blood causing inﬂammation and tissue
injury at distant sites [24–31]. Periodontal treatment has
been shown to reverse some of these systemic adverse eﬀects
[32–34].
A link between poor oral hygiene and HNSCC has been
suggested for over two decades [35–46] but the underlying
mechanismofthisassociationwasnotclear.Studiesfromour
group have suggested that chronic periodontitis, an outcome
of poor oral hygiene, is associated with oral premalignant
lesions [47]a n dH N S C C[ 48, 49]. In a secondary analysis
of the Third National Health and Nutrition Examination
Survey (NHANES III), a large nationwide cross-sectional
study, including 13,798 men and women of age 20 and older,
a history of periodontitis, measured by clinical attachment
loss (CAL), was signiﬁcantly associated with the prevalence
oforalpremalignantlesions(OR=1.55,95%CI=1.06–2.27)
after adjusting for age, gender, race/ethnicity, education,
tobacco,alcohol,andoccupationalhazard[47].Periodontitis
was not associated with the presence of any oral soft tissue
lesion (OR = 1.09, 95% CI = 0.91–1.31) (Table 2)[ 47].
In a recent hospital-based case-control study with his-
tologically conﬁrmed 266 primary incident HNSCC cases
Table 2: Risk of oral premalignant lesions from periodontitis.
Premalignant lesions∗ Any lesion
N (%)† 323 (2.3%) 3,421 (24.8%)
Periodontitis‡ 1.55 [1.06–2.27]§ 1.09 [0.91–1.31]
∗Premalignant lesions were deﬁned as erythroplakia, leukoplakia (homo-
geneous and nonhomogeneous), nonspeciﬁc ulcer, and smokeless tobacco-
associated lesions.
†Count (percentage).
‡Periodontitis was deﬁned as CAL >1.5mm.
§Odds ratios (OR) and their 95% conﬁdence intervals derived from
multiple logistic regression analysis adjusting for age, gender, race/ethnicity,
education, tobacco, alcohol, and occupational hazard.
and 207 controls in Upstate New York, ABL was signiﬁcantly
higher in cases compared to controls (4.04mm versus
2.44mm, P<0.001). After adjustment for age, gender,
race/ethnicity, marital status, smoking status, alcohol use,
and missing teeth, each millimeter of ABL was associated
with >4-fold increased odds of HNSCC (OR = 4.36, 95% CI
= 3.16–6.01). The strength of the association was greatest in
the oral cavity (OR = 4.52, 95% CI = 3.03–6.75), followed by
oropharynx(OR=3.64,95%CI=2.54–5.22)andlarynx(OR
= 2.72, 95% CI = 1.78–4.16) (Table 3). Furthermore, patients
with periodontitis were more likely than those without
periodontitis to have poorly diﬀerentiated oral cavity SCC
(32.8% versus 11.5%, P = 0.038) [49].
The potential association between chronic inﬂammation
and HNSCC is further supported by two recent case control
studies suggesting a beneﬁcial eﬀect of nonsteroidal anti-
inﬂammatory drugs (NSAID) against HNSCC [50, 51]. In
a hospital-based case control study among 529 patients with
HNSCC and 529 control subjects matched by age, sex, and
smoking status, Aspirin use was associated with a 25%
reduction in the risk of HNSCC (OR = 0.75; 95% CI =
0.58–0.96). Risk reduction was observed across all primary
tumor sites, with cancers of the oral cavity and oropharynx
exhibiting greater risk reduction [50]. In another more
recent hospital-based case-control study among 71 incident
HNSCC cases and 71 healthy controls, daily NSAID use wasInternational Journal of Otolaryngology 3
Table 3: Association between periodontitis and head and neck cancer stratiﬁed by tumor site (N = 473).
Alveolar bone loss (per millimeter) N (cases/controls) Crude OR [95% CI]∗ Adjusted† OR [95% CI]
All HNSCC patients 266/207 3.85 [2.96–5.01] 4.36 [3.16–6.01]
Oral cavity SCC patients 100/207 3.26 [2.44–4.36] 4.52 [3.03–6.75]
Oropharyngeal SCC patients 115/207 3.06 [2.29–4.07] 3.64 [2.54–5.22]
Laryngeal SCC patients 51/207 3.75 [2.60–5.41] 2.72 [1.78–4.16]
∗Odds ratios and their 95% conﬁdence intervals.
†Adjusted odds ratios were derived from multiple logistic regression analysis including age at diagnosis, gender, race/ethnicity, marital status, smoking status,
alcohol use, ABL, and missing teeth.
associated with 86% reduction in HNSCC risk (OR = 0.14;
95% CI = 0.04–0.54) after adjusting for educational level and
marital status [51].
The biological mechanism of the association between
chronic inﬂammation and cancer has been described
extensively but is also evolving continuously since both
inﬂammation and cancer are complex processes under the
control of many driving forces [15–18]. Bacteria and their
products, including endotoxins, enzymes, and metabolic
by-products, may directly induce genetic and epigenetic
changes in surrounding epithelial cells [52–54]. They also
increase the production of carcinogenic acetaldehydes [55–
57] and nitrosamines [58, 59]. However, the bulk of the
available evidence supports an indirect association through
stimulation of inﬂammation. Host cells, including neu-
trophils, macrophages, monocytes, lymphocytes, ﬁbroblasts,
and epithelial cells, respond to bacteria by generating
(1) cytokines, chemokines, prostaglandins, growth factors,
and other signals that provide an environment for cell
survival, proliferation, migration, angiogenesis, and inhibi-
tion of apoptosis [60]. This environment helps epithelial
cells to accumulate mutations, and drives these mutant
epithelial cells to proliferate and migrate and gives them
a growth advantage; (2) reactive oxygen species (hydro-
gen peroxide and oxy radicals), reactive nitrogen species
(nitric oxides), reactive lipids and metabolites (malondialde-
hyde, 4-hydroxy-2-nonenal), and matrix metalloproteinases
(MMPs) which can act as endogenous mutagens. Numerous
in vivo and in vitro studies have conﬁrmed the associations
of several genes and proteins involved in diﬀerent stages of
inﬂammation with carcinogenesis [61–71]. In addition to
its independent association with HNSCC, chronic inﬂam-
mation may also act synergistically with other carcinogens
to increase the risk of HNSCC. For example, breaks in the
mucosal barrier due to chronic inﬂammation may lead to
enhanced penetration of other carcinogens such as tobacco,
alcohol, and dietary metabolites [72, 73].
3. ChronicInﬂammation and
Oral HPVInfection
The steady increase in the incidence of oropharyngeal
cancers over the last four decades has been mainly attributed
to oral HPV infection which has been accepted as an
etiological factor for a subset of HNSCC [10–14]. HPV
is a commonly transmitted virus but the majority of the
infections are cleared rapidly by the immune system. Rather
than its mere presence at one time point, persistence of the
virus seems to be the critical factor for the development of
HPV-related diseases [74, 75]. Therefore, targeting factors
associated not only with the acquisition but also with the
persistence of oral HPV infection will contribute to both
prevention and treatment.
HPV is a small DNA virus with a speciﬁc tropism
for squamous epithelia. More than 120 diﬀerent HPV
types have been isolated to date. Low-risk HPVs, including
HPV-6 and HPV-11, induce benign hyperproliferations of
the epithelium such as papillomas or warts which rarely
progress to cancer [76]. High-risk oncogenic types such
as HPV-16 and HPV-18 are associated with squamous cell
carcinoma.HPV-16andHPV-18arecapableoftransforming
epithelial cells. This transforming potential is largely a
result of the function of two viral oncoproteins, E6 and
E7, which inactivate two tumor suppressor proteins, p53
and pRb, respectively. Expression of E6 and E7 results in
cellular proliferation, loss of cell cycle regulation, impaired
cellular diﬀerentiation, increased frequency of mutations,
and chromosomal instability [76, 77].
Population-based studies estimate that the prevalence
of HPV DNA in normal oral mucosa is 5–10% [14, 76].
In contrast with cervical cancer, in which HPV is present
100% of the time, HPV is present at a smaller and variable
percentage in HNSCC, depending on the subsite and the
geographic region studied. In a review of 60 studies, the
prevalence of HPV DNA was 23.5% in oral cavity SCC,
35.6% in oropharyngeal SCC, and 24.0% in laryngeal SCC
[78]. HPV-16 accounted for a larger majority of HPV-
positive oropharyngeal SCC (86.7%) compared with HPV-
positive oral cavity SCC (68.2%) and HPV-positive laryngeal
SCC (69.2%). Conversely, HPV-18 was rare in HPV-positive
oropharyngeal SCC (2.8%) compared with HPV-positive
oral cavity SCC (34.1%) and HPV-positive laryngeal SCC
(17.0%). Aside from HPV-16 and HPV-18, other oncogenic
H P VD N A sw e r er a r e l yd e t e c t e di nH N S C C[ 78]. In a multi-
national study conducted by the International Agency for
Research on Cancer (IARC), only 18% of oropharyngeal
tumors were HPV-positive [4]. In the majority of recent
studies, >50% of oropharyngeal SCC contained the HPV
DNA [10–14]. Probability of HPV DNA being detected in
theoralmucosaincreaseswithincreasingdegreeofdysplasia.
Overall, HPV DNA is 2- to 3-times more likely to be detected
in premalignant lesions and about 5-times more likely to be
detected in HNSCC compared to normal oral mucosa [79].
HPV-positive HNSCCs have a unique risk factor proﬁle.
These tumors are more common in younger patients, have
a male predominance, are often staged higher, yet have4 International Journal of Otolaryngology
a survival advantage. These patients are less likely to have
used tobacco and alcohol excessively [14]. Pathologically,
they are more likely to be basaloid type (poorly diﬀer-
entiated) and lack keratinization. The p16 protein, also
known as cyclin-dependent kinase 4 (CDK4) inhibitor,
is upregulated in HPV-positive HNSCC, and may serve
as a surrogate marker for HPV transcriptional activity.
Molecularly, these tumors expresses oncoproteins E6 and
E7 demonstrate less chromosomal disruption than HPV-
negative HNSCC. Tumor suppressor genes p53 and pRb are
usually intact, but the expressed proteins are inactivated by
the viral oncoproteins E6 and E7, respectively. In contrast,
HPV-negativeHNSCC,whichisusuallyinitiatedbysmoking
and alcohol, shows considerable chromosomal aberration,
including mutation of the p53 gene in 50% of cases [80–82].
Although the natural history of cervical HPV infection
is well established, the mechanism of transmission for oral
HPV infection, which has a distinct immunologic environ-
ment, is largely unknown. There is increasing evidence that
oral HPV transmission may be related to sexual history, and
particularly oral sexual behavior. Case-control studies have
shown associations of oral HPV infection with the number
of oral and genital sexual partners, age at ﬁrst of oral-genital
contact, frequency of sexual contacts, and history of genital
warts [83–85]. Vertical transmission of oral HPV infection
through maternal milk is also possible [86]. HPV infection
at each anatomic site is localized and concordance of oral
and genital HPV infection seems to be low [14] implying the
importance of local oral factors. Research evaluating the role
of local oral factors on natural history of oral HPV infection
is lacking and is critical to develop eﬀective prevention
strategies.
Few epidemiological studies suggest that chronic inﬂam-
mation of the cervix increases the risks of HPV infection
and cervical cancer [87–90]. In addition, molecular studies
have shown that inﬂammatory cytokines, including IL-1, IL-
6,andTNF-α,modulateproliferationofHPVandexpression
of its oncogenes E6 and E7 in cervical epithelial cells [91–
96]. Supporting these ﬁndings, an in vitro study has shown
that a nonsteroidal anti-inﬂammatory drug strongly induced
degradation of the HPV oncoproteins causing growth arrest
and apoptosis in cervical carcinoma cells in a concentration-
dependent manner [97]. Continuous expression of the
HPV oncoproteins has also been shown to be critical for
the maintenance of malignant phenotype in HPV-positive
oropharyngeal cancers [98]. The oral cavity and cervix are
lined with similar types of mucosa, and the same HPV
types cause cervical and head and neck cancers. In a recent
hospital-based case-control study with 30 incident primary
base of tongue SCC, a history of chronic periodontitis was
associated with tumor HPV status after adjustment for age at
diagnosis,gender,race/ethnicity,alcoholuse,smokingstatus,
ABL, and number of missing teeth (OR = 3.96, 95% CI =
1.18–13.36) (Table 4)[ 99].
An association between chronic inﬂammation and HPV
infection is biologically plausible. HPV infects basal cells
of the epithelium exclusively, and it usually gains access
through microabrasions. In addition, replication of the virus
is closely associated with basal cell proliferation [74, 75].
Table 4: Odds Ratios for Tumor HPV Status Associated with
Periodontal Variables.
Crude OR Adjusted† OR
[95% CI]∗ [95% CI]
Alveolar Bone Loss
(per millimeter) 2.86 [1.03–7.98] 3.96 [1.18– 13.36]
Missing Teeth
(per tooth) 0.94 [0.86–1.02] 0.95 [0.74–1.21]
∗Odds ratios and 95% conﬁdence intervals.
†Adjusted odds ratios were derived from multiple logistic regression model
including age at diagnosis, gender, race/ethnicity, alcohol use, smoking
status, ABL and number of missing teeth.
Mucosal injury and consequent breaks within the oral
mucosa mediated by inﬂammatory cytokines may facilitate
the acquisition as well as the persistence of oral HPV
infection[70].Inthepresenceofchronicinﬂammation,basal
cell proliferation is also increased leading to higher viral
load in saliva as well as higher risk of transmission [75].
The observed association between periodontitis and oral
HPV infection may be alternatively explained by the direct
eﬀects of bacteria [100]. Prospective cohort studies have
shownthatconcurrentinfectionwithChlamydiatrachomatis
increased the persistence of cervical HPV infection and
the risk of cervical cancer [101, 102]. Periodontal bacteria,
derived from periodontal pockets, are extensively present
in the oral mucosa [103, 104]. However, whether the asso-
ciation between periodontitis and oral HPV infection is
through direct eﬀects of bacteria or through stimulation of
inﬂammation is yet to be determined. It is likely that both
mechanismsareinvolvedbutthebulkofthecurrentevidence
suggests that the periodontal bacteria travel from aﬀected
tissues to distant sites via saliva and bloodstream and cause
tissue injury through inﬂammatory reactions [105–109].
4. Implications for Prevention and Treatment
The potential role of chronic inﬂammation in the etiology of
HNSCC is summarized in Figure 1. Brieﬂy, chronic inﬂam-
mation may increase the risk of HNSCC both independently
and by facilitating the acquisition and persistence of oral
HPV infection.
Understanding the interactions among risk factors may
be the most important step towards eﬀective prevention
and treatment of HNSCC. It is well established that car-
cinogenesis is a multifactorial process and the presence of a
single risk factor is usually not suﬃcient to cause cancer. Yet,
most studies have focused on independent eﬀects of speciﬁc
risk factors [6, 7]. Recently, two separate entities, “tobacco-
related” and “HPV-related” HNSCC, have been suggested
[80–82]. However, this classiﬁcation overlooks the fact that
most HPV-positive HNSCC patients also have a history of
tobacco use. It is more likely that the interaction between
diﬀerent combinations of risk factors in each individual
determines the disease outcome or its clinical presentation.
For example, in our study population consisting of newly
diagnosed base of tongue cancer patients, 83.5% had a
smoking history and 63.3% had HPV-positive tumors.International Journal of Otolaryngology 5
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Figure 1: Model for the role of chronic inﬂammation in the etiology of head and neck squamous cell carcinoma (HNSCC).
The majority (71.4%) of patients with HPV-positive tumors
alsohadasmokinghistory[99].Theresultsfurthersuggested
that smokers with chronic periodontitis were more likely to
have HPV-positive tumors, and smokers without periodon-
titis history were more likely to have HPV-negative tumors
[99].Smokingisastrongriskfactorforchronicperiodontitis
[21]. Although validation with further studies is needed,
these observations suggest that only a subset of smokers who
develop chronic inﬂammatory diseases (perhaps long-term,
moderate to heavy smokers) are at increased risk for oral
HPV infection.
Saliva provides a means of interaction between diﬀerent
carcinogens. It also provides a means of transport from one
surface to another promoting disease at distant sites. Sali-
vary enzymes also metabolize tobacco, alcohol, and dietary
components into carcinogens [110]. This may contribute to
the ﬁeld cancerization in the head and neck region. The
fact that the majority of HNSCC occurs at saliva-draining
areas supports this hypothesis [111]. While periodontitis
is localized to the structures around teeth, periodontal
pocket contents, including bacteria, viruses, inﬂammatory
cytokines, enzymes, and toxins are continuously shed into
saliva [22, 23, 112]. On the other hand, saliva has no access
into periodontal pockets. Therefore, periodontal pockets are
probably a source of inﬂammatory and microbial markers in
saliva rather than being the actual sites of carcinogenesis.
Itiscriticaltounderstandthecharacteristicsofthedental
bioﬁlm to eﬀectively treat periodontitis. Bioﬁlms are sessile
communities of bacteria embedded in a polymeric matrix
irreversibly attached to a surface. The bacteria in the bioﬁlm
diﬀer profoundly from their free-ﬂoating counterparts and
are resistant to antimicrobials as well to host defense
[113]. Thus, eﬀective treatment of periodontitis is based
on mechanical removal of the bioﬁlm. In the initial stages
of the disease, a thorough professional dental cleaning and
maintenance of a good personal oral hygiene, by brushing
and ﬂossing, is usually suﬃcient to reverse the disease
process. In more advanced stages, however, the bioﬁlm or
calculus in periodontal pockets is inaccessible by personal
oral hygiene practices. In these cases, surgical reduction
of the periodontal pockets and/or periodic professional
cleanings may be necessary to control the disease [19, 113].
If prospective studies conﬁrm that chronic local inﬂam-
mation is in fact a signiﬁcant player in the natural histories
of oral HPV infection and HNSCC, this may have important
implications, not only for prevention, but also for treatment.
Chronic local inﬂammation, such as periodontitis, is easy to
detect and may represent a clinical high-risk proﬁle for both
oral HPV infection and HNSCC. Subjects with sources of
chronic inﬂammation in the oral cavity may be screened for
oral HPV infection and HNSCC for early diagnosis.
5. Conclusion
Chronic local inﬂammation, both independently and by
facilitating oral HPV infection, may be an important player
in the etiology of HNSCC.
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